Sara Pérez Jaume
Ayudante de investigación
Research group
Professional network profiles
Last Publications
- Esther Martínez García, López de San Roman Fernández C, Nishishinya Aquino MB, Pérez-Jaume S, Fernández-Jané C, Cruz-Martínez O and Morales-La Madrid A Patient Acceptability of the First Integrative Pediatric Oncology Unit in Spain-The Pediatric Cancer Center Barcelona Experience: A Retrospective Study Cancers . 17(2): .
- Pérez-Jaume S and Carrasco, Josep L. Comparison of optimum threshold estimators in the binormal setting JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION . : .
- Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes PEDIATRIC BLOOD & CANCER . 71(10): .
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Nuevas técnicas para la caracterización molecular completa y la mejora del seguimiento de la enfermedad mínima residual en leucemia aguda pediátrica
- Leader
- Mireia Camós Guijosa, Nerea Vega García
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00213
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Desarrollo de clasificadores epigenéticos para el Cáncer Pediátrico (ECPC)
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI20/00519
- Starting - finishing date:
- 2021 - 2025
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
More activities
-
Defensa tesi doctoral: Sara Pérez Jaume
Auditorio J Plaza del Hospital Sant Joan de Déu y online